NF-κB in cancer therapy

Arch Toxicol. 2015 May;89(5):711-31. doi: 10.1007/s00204-015-1470-4. Epub 2015 Feb 18.

Abstract

The transcription factor nuclear factor kappa B (NF-κB) has attracted increasing attention in the field of cancer research from last few decades. Aberrant activation of this transcription factor is frequently encountered in a variety of solid tumors and hematological malignancies. NF-κB family members and their regulated genes have been linked to malignant transformation, tumor cell proliferation, survival, angiogenesis, invasion/metastasis, and therapeutic resistance. In this review, we highlight the diverse molecular mechanism(s) by which the NF-κB pathway is constitutively activated in different types of human cancers, and the potential role of various oncogenic genes regulated by this transcription factor in cancer development and progression. Additionally, various pharmacological approaches employed to target the deregulated NF-κB signaling pathway, and their possible therapeutic potential in cancer therapy is also discussed briefly.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Humans
  • NF-kappa B / physiology*
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Antineoplastic Agents
  • NF-kappa B